Bacteria are often perceived as mere pathogens that threaten human health. However, their evolutionary history includes the adaptation of intricate defense mechanisms designed to counteract viral infections. Wood and his research team explored one such mechanism stemming from ancient, dormant viruses residing within bacterial cells. These cryptic prophages have long been understood to incorporate their genetic material into the host’s DNA, yet their active roles in defending against new viral threats had been understudied until now.

The team’s findings, recently published in the distinguished journal Nucleic Acids Research, underscore the potential for leveraging these bacterial systems to develop stronger antivirus platforms tailored for various industries, including healthcare and food safety. As the research community becomes increasingly aware of the limitations associated with traditional antibiotic treatments due to rising antibiotic resistance, the search for alternative therapies has intensified. Interestingly, Wood’s research highlights the plausible use of viral agents themselves as a means to control bacterial populations.

Wood’s study centered on the function of a specific enzyme known as recombinase, which plays a crucial role in this defense mechanism. The discovery that recombinase not only exists within viral contexts but is also integral to bacterial antiviral strategies challenges the conventional understanding of bacterial genetics and their response to viral invasions. The exact recombinase identified, called PinQ, operates by not only recognizing viral incursions but also instigating genetic alterations in the bacterial DNA to bolster its defenses.

Upon the detection of a virus, the PinQ enzyme induces a genetic inversion—essentially flipping specific segments of DNA within the bacterial chromosome. This inversion leads to the production of two novel chimeric proteins consisting of genetic material derived from both the bacterial host and the incorporated prophage. The adaptations result in proteins collectively referred to as Stf, which effectively thwart viral attachment and invasion. Wood emphasizes the significance of this mechanism, stating that instead of resulting in non-functional proteins, as is often the case with genetic mutations, this precise inversion creates viable defense proteins that reflect the evolutionary prowess of bacteria.

The implications of these findings extend well beyond theoretical discussions. Wood notes that the profound increase in antibiotic-resistant diseases is fueled, in part, by the excessive and often inappropriate use of antibiotics. By utilizing viruses as a targeted approach against antibiotic-resistant strains, there is a dual opportunity: manage bacterial infections with precision while minimizing reliance on traditional antibiotics. This paradigm shift in thinking could revolutionize infection control in clinical settings, offering new pathways to manage ailments caused by resilient bacteria.

While previous studies have acknowledged the presence of recombinase enzymes in bacterial systems, Wood’s research is groundbreaking in revealing their explicit role as antiviral agents. Researchers have often regarded these enzymes as incidental markers associated with viral DNA, overlooking their essential contributions to the host’s defense mechanisms. Wood explains, “To effectively defend against viruses, bacteria must possess a complexity of defense systems. Our findings introduce yet another layer of sophistication to this ongoing arms race.”

In experimental settings, the Wood team’s methods included overproducing Stf proteins within E. coli samples, subsequently exposing them to viruses. By analyzing the turbidity of these samples—essentially measuring how cloudy or clear they were—the researchers could draw conclusions regarding viral infection rates. Higher turbidity levels signified fewer viruses successfully infiltrating the bacterial population, demonstrating the efficacy of the adaptive proteins generated.

Notably, the team’s studies also indicated that while this defense mechanism is initially effective, evolutionary pressures from the viruses themselves can lead to adaptations that allow the pathogens to overcome these defenses. For example, after several experimental iterations, the viruses managed to alter their surface proteins to attach to the modified bacteria more effectively. This dynamic interplay showcases the continual evolution between bacterial defenses and viral adaptability, illustrating the complexity and persistence of these microorganisms in their environmental niches.

The broader impact of this research cannot be overstated. By fostering a comprehensive understanding of how antivirus systems function within bacteria, scientists can enhance food production methods, especially in fermentation processes integral to industries such as dairy. As Wood highlights, building on this knowledge will empower future investigations into additional prophages within their lab, each of which may hold untapped potential for antiviral strategies.

As Wood poetically remarks, “This story revolves around how a fossil protects its host from an invader, pulling back the curtain on evolutionary dynamics that underscore modern science’s ability to manipulate biological processes.” Such narratives remind us of the intricate relationships that exist within ecosystems, where even dormant viruses can play crucial roles in the survival of their hosts.

The research sheds light on the vast untapped reservoir of defense mechanisms that bacteria may possess, encouraging a paradigm shift in how we approach bioengineering, medical therapeutics, and our understanding of microbial evolution. It paints an engaging picture of the unseen battles in microbial communities and challenges scientists to rethink how they harness these biological entities safely and effectively.

In conclusion, Thomas Wood and his team’s discoveries offer crucial insights into bacterial defenses against viral threats, establishing novel avenues for research that promise to enhance clinical practices. As we navigate a world increasingly affected by antibiotic resistance and viral infections, the balance of power in bacterial-viral interactions holds both a warning and an invitation for innovation in medical science.

Subject of Research: Cells
Article Title: Adsorption of phage T2 is inhibited due to inversion of cryptic prophage DNA by the serine recombinase PinQ
News Publication Date: 16-Oct-2025
Web References: Nucleic Acids Research
References: DOI
Image Credits: Credit: Poornima Tomy/Penn State

Keywords

Microbiology, Bacterial Defense Mechanisms, Viral Interaction, Recombinase, Antibiotic Resistance.

The essence of this research lies in understanding how ultrasound waves can interact with these specially engineered nanovesicles. These vesicles are designed to respond to ultrasound, allowing them to change shape and release their contents at precise moments. This controllability offers researchers the ability to orchestrate cellular processes, fundamentally changing how we approach cellular therapies and drug development.

Ultrasound as a tool for biological manipulation has existed for some time, but the application of ultrasound-responsive nanovesicles is relatively novel. Researchers postulate that this method not only enhances cellular uptake of therapeutic agents but also protects these agents from degradation before they reach their target site. This capability addresses a significant challenge in traditional drug delivery systems, potentially leading to improved efficacy and reduced side effects for patients.

The nanovesicles developed by the team are composed of biocompatible materials, which make them suitable for in vivo applications. The researchers meticulously designed these vesicles to be stable under normal conditions while remaining responsive to specific ultrasound frequencies. This dual behavior allows for a safe and efficient drug delivery mechanism that can be activated without the need for invasive techniques.

In an extensive series of experiments, the team demonstrated that when exposed to targeted ultrasound frequencies, the nanovesicles could effectively release their therapeutic cargo. This demonstrated release mechanism allowed for a spike in the metabolic activity of the cells exposed to these vesicles. The data suggested that this increased activity could potentially lead to enhanced cellular repair processes, making it a promising avenue for regenerative medicine.

Additionally, the research highlighted the potential for these ultrasound-responsive nanovesicles to be applied in the treatment of various metabolic disorders. Conditions such as obesity, diabetes, and muscular dystrophies could benefit from enhanced cellular metabolism induced by this technology. As metabolic dysregulation is a central issue in these diseases, targeted metabolic reprogramming can aid in restoring normal function to affected tissues.

One of the most exciting implications of this research also lies in its potential for personalized medicine. By utilizing specific patient data to determine the optimal ultrasound frequencies and therapeutic agents for individual cases, healthcare providers could tailor treatments that maximize effectiveness while minimizing adverse effects. This personalized approach could revolutionize treatment protocols for chronic diseases that currently have limited management options.

The findings of this research open new avenues for understanding cell signaling and metabolic pathways. By combining nanotechnology with ultrasound, researchers can probe metabolic processes at unprecedented levels of precision. This not only enhances our understanding of cellular behavior but also raises intriguing questions regarding the fundamental mechanisms that underpin metabolic control in living organisms.

As with any groundbreaking research, challenges remain. The translation of these findings from bench to bedside requires extensive clinical testing to ensure safety and efficacy. Regulatory pathways for new therapies utilizing nanotechnology are complex, and addressing these will be crucial for future applications. However, the groundwork laid by Hsu and colleagues paves the way for further exploration of therapeutic strategies and their potential impact on disease management.

Furthermore, insights gained from this research may encourage a more integrated approach to treatment development. Embracing interdisciplinary collaboration across fields such as biology, engineering, and medicine will be vital in translating these innovative ideas into practical applications. As more researchers become aware of the potential of ultrasound-responsive nanovesicles, the pace of discovery in this realm is likely to accelerate.

In conclusion, the work undertaken by Dr. Hsu’s team represents a significant step forward in metabolic reprogramming. The application of ultrasound-responsive nanovesicles heralds a new era of precision medicine, offering tantalizing prospects for enhancing cellular function and combating metabolic diseases. This study not only expands our understanding of cellular behavior but also provides actionable insights that could shape the future of therapeutic development.

The potential for revolutionary change driven by this research is tantalizing. As scientists continue to explore the scope of ultrasound-responsive technology, we remain on the cusp of a new chapter in medical science that could redefine the possibilities of treatment, paving the way for next-generation therapies that are both more effective and safer for patients.

Through continued investigation and innovation, the implications of these findings could resonate across multiple fields, from drug development to regenerative medicine, ultimately transforming the landscape of healthcare. The fusion of nanotechnology and ultrasound may not just alter how we treat diseases but may also redefine our fundamental understanding of metabolic processes and the possibilities of cellular manipulation.

The future of medical treatment is ever-brightening with the promise shown by ultrasound-responsive nanovesicles. This pioneering research serves as a beacon of hope, guiding us toward more effective, efficient, and targeted therapeutic strategies in our relentless pursuit of health and healing.

Subject of Research: Metabolic reprogramming using ultrasound-responsive nanovesicles

Article Title: Metabolic reprogramming with ultrasound-responsive nanovesicles

Article References:

Hsu, J.C., Zhou, J. & Cai, W. Metabolic reprogramming with ultrasound-responsive nanovesicles.
Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01460-2

Image Credits: AI Generated

DOI: 10.1038/s41551-025-01460-2

Keywords: Metabolic reprogramming, ultrasound-responsive, nanovesicles, drug delivery, tissue engineering, regenerative medicine, personalized medicine.

Professor José Ramón Bilbao, a leading geneticist at EHU and co-lead author of this pivotal study, emphasizes the underappreciated potential of saliva in medical diagnostics. “Saliva is one of the most accessible biological fluids but it is still underutilised in clinical practice,” he explains. The research highlights that saliva contains molecular markers reflective of systemic pathological processes, which means it could serve as a window into diseases affecting organs and tissues far beyond the oral cavity.

The scientific team meticulously analyzed saliva samples obtained from over 350 individuals, focusing on the cataloging of single nucleotide polymorphisms (SNPs)—the minute variations in DNA sequence known to influence gene function. Their approach concentrated on determining how these polymorphisms, essentially genetic switches, modulate gene activity. These SNPs were found not just to exist in saliva but to exert functional effects that parallel those identified in blood-based studies of genome function and disease susceptibility.

A striking outcome of the research was the demonstration that many of the SNPs detected within saliva samples are significantly associated with an elevated risk for a multitude of common chronic diseases. These include, but are not limited to, prostate cancer, coronary artery disease, Parkinson’s disease, and Type 2 diabetes. This observation aligns with large-scale international genome-wide association studies (GWAS) previously conducted on blood-derived DNA, thereby validating saliva as an equivalent medium for detecting disease-relevant genetic variants.

Beyond identifying risk-associated polymorphisms, the scientists employed sophisticated statistical modeling to assess the contribution of saliva-based genetic markers to heritability estimates of complex diseases. Intriguingly, their analyses revealed that saliva-derived SNPs could explain a considerable portion of genetic heritability, in some instances outperforming traditional blood biomarkers. This raises the prospect of saliva potentially offering more precise genetic risk stratification in clinical settings.

While the research is poised to revolutionize non-invasive diagnostics, the investigators underscore the necessity for validation in expanded cohorts and diverse populations to fully establish clinical utility. Alba Hernangómez-Laderas, a molecular biologist and co-lead on the project, underscores this point: “This work opens the door to developing saliva-based testing that could in the future be used for the early detection of diseases or for monitoring treatments, without the need to extract blood or perform other invasive procedures.”

The implications of this work are both profound and practical, predicting a future where saliva-based tests become routine tools in preventive medicine and personalized healthcare. The minimal discomfort and ease of repeated sample acquisition position saliva as an ideal biofluid for longitudinal monitoring of disease progression and therapeutic response, potentially reshaping patient compliance and engagement.

An additional cornerstone of the study was the development of the largest publicly accessible genetic database derived from saliva samples. Hosted via an open-access platform, this genetic repository is designed to stimulate innovative research and foster collaboration across biomedical disciplines. Researchers worldwide will be able to leverage this resource to explore novel diagnostic markers and genetic architectures of disease.

This research forms part of a collaborative effort involving eight additional researchers from EHU and partnering institutions including BioGipuzkoa, BioBizkaia, and the Icahn School of Medicine at Mount Sinai in New York. The interdisciplinary nature of the team reflects the complexity of translating molecular genetic discoveries into clinical practice, weaving together expertise from genomics, biostatistics, and clinical medicine.

At its core, this study challenges the current paradigm that prioritizes blood samples for genome-based diagnostics. By demonstrating that saliva harbors equivalent or superior genetic information relevant to systemic diseases, it lays the groundwork for more accessible, cost-effective, and patient-friendly diagnostic methodologies. Such progress aligns with the global pursuit of precision medicine, where non-invasive, rapid, and accurate testing modalities are paramount.

The potential for saliva to act as a diagnostic medium is particularly timely given the ongoing push toward decentralized healthcare and community-based testing facilities. Saliva’s collection simplicity obviates the need for trained phlebotomists and stringent cold-chain logistics, thereby broadening access to genetic testing in underserved or remote areas, and enabling large-scale screening programs.

As exciting as these findings are, the authors caution that rigorous longitudinal studies and regulatory evaluations are required before saliva-based genetic tests can be incorporated into routine clinical protocols. Nonetheless, the foundational data generated by this study constitute a significant leap forward, elevating saliva from a diagnostic curiosity to a bona fide molecular goldmine.

In summary, this pioneering research underscores saliva’s vast promise as a non-invasive, informative, and practical surrogate for blood in genomic medicine. The identification of functional DNA methylation biomarkers within saliva heralds a new era for the early detection and management of multifactorial diseases, leveraging the genetic fingerprints embedded in our most accessible bodily fluid.

Subject of Research: Saliva as a diagnostic medium for DNA methylation biomarkers indicating disorders beyond oral health

Article Title: Saliva as a potential diagnostic medium: DNA methylation biomarkers for disorders beyond the oral cavity

News Publication Date: 20-Jun-2025

Web References:
https://doi.org/10.1038/s41525-025-00509-0

References:
Alba Hernangómez-Laderas, Ariadna Cilleros-Portet, Sergi Marí, Bárbara P. González-García, Ane Arregi, Alba Jimeno-Romero, Amaia Irizar, Iraia García-Santisteban, Corina Lesseur, Nora Fernandez-Jimenez, José Ramón Bilbao. Saliva as a potential diagnostic medium: DNA methylation biomarkers for disorders beyond the oral cavity. npj Genomic Medicine, 10, 49 (2025).

Image Credits:
Photo: Egoi Markaida. EHU

Keywords:
Saliva, Body fluids, Cancer, Cancer research, Heart disease, Parkinson’s disease

Immunotherapy, particularly Chimeric Antigen Receptor (CAR) T cell therapy, has already redefined the landscape of hematologic cancers such as leukemia and lymphoma by harnessing the patient’s own immune cells to eradicate malignant cells. The process involves extraction of T cells, their genetic reprogramming with a synthetic receptor, and reinfusion into the patient’s bloodstream. Despite its seminal success against blood cancers, this modality faces formidable hurdles when applied to solid tumors. The tumor microenvironment’s complexity and the difficulty of CAR T cells to adequately recognize and penetrate solid masses call for novel receptor configurations and sophisticated cell engineering approaches.

The combinatorial explosion of possible CAR T cell designs, coupled with the growing wealth of accumulated experimental data and literature, presents a daunting analytical challenge. To tackle this, Miskov-Zivanov aims to build an AI-powered system capable of sifting through vast bodies of scientific literature and heterogeneous data repositories to integrate expert knowledge and raw experimental insights. This system will intelligently recommend superior therapeutic lymphocyte designs, including both CAR T cells and tumor-infiltrating lymphocytes (TILs), by synthesizing disparate sources of information into actionable engineering guidance.

Drawing on her unique background as a computer engineer with extensive postdoctoral experience in computational and systems biology, Miskov-Zivanov emphasizes automation in a field traditionally dominated by labor-intensive manual processes. She envisions her computational framework as a catalyst that automates the complex tasks typically performed by biologists, thereby accelerating and refining the design cycle for immunotherapeutic cells. This aspiration springs from her conviction that the convergence of computation and biology can unveil novel pathways that manual curation might never reveal.

Building on her earlier NSF-funded EAGER award, which developed a prototype tool utilizing Natural Language Processing (NLP) to extract pertinent data from scientific texts, she now evolves the approach to incorporate state-of-the-art large language models (LLMs) and neural networks. This hybrid system will not only parse and analyze scientific papers but also interpret experimental datasets to conduct comprehensive in silico experiments. By simulating thousands of potential cell designs computationally, this framework will perform hypothesis-driven screening prior to laboratory validation.

A critical innovation in Miskov-Zivanov’s project lies in developing improved prompting techniques for AI models, enabling more precise and relevant extraction of meaningful data from the overwhelming corpus of biomedical literature. Instead of forcing researchers to navigate tens of thousands of papers, many irrelevant to their queries, the system will pinpoint high-impact insights and knowledge, distilling the essence of complex biological narratives. This capability could dramatically reduce time and resources consumed in immunotherapy research and design.

To represent and utilize the extracted knowledge efficiently, Miskov-Zivanov converts science-derived data into knowledge graphs (KGs)—structured semantic networks encoding relationships among biological entities like proteins, signaling pathways, and cellular behaviors. These KGs serve as a scaffolding layer upon which graph neural networks (GNNs) operate. GNNs, leveraging their prowess in modeling graph-structured data, analyze interconnections within the KGs to predict the efficacy of various immunotherapeutic cell configurations. This synergistic blend amplifies predictive accuracy beyond what isolated datasets or traditional statistical models can achieve.

Understanding the imperative for educating emerging engineers in these frontier methodologies, Miskov-Zivanov has introduced a novel graduate-level course focused on knowledge graphs and their construction, interpretation, and application. She believes that equipping the next generation of researchers with computational tools capable of integrating structured knowledge and data-driven learning models is vital for addressing increasingly complex biomedical challenges. By nurturing interdisciplinary expertise, this educational initiative seeds future innovation in synthetic biology and therapeutic design.

Underlying this ambitious technological endeavor is the goal to establish a reliable methodology for engineering and systematically testing thousands of immunotherapeutic cell designs with diverse receptor systems. Success could catalyze breakthroughs in developing cellular therapies that effectively infiltrate and neutralize solid tumors—an enduring challenge in oncology. Moreover, the project aspires to contribute novel algorithmic innovations to identify, present, and validate trustworthy predictive data in biomedical research.

Reflecting on her motivation, Miskov-Zivanov shares a poignant narrative of how a childhood news story about a young leukemia patient cured by immunotherapy ignited her passion. Her dual lens as a computer engineer and a scientifically curious individual fuels her drive to forge impactful applications of computing technologies in life-saving medical research. Her work epitomizes the compelling convergence of artificial intelligence and biotechnology, promising to reshape cancer treatment paradigms.

Her department chair, Alan George, lauds her as a rising star and innovator whose research lab, the MeLoDy (Mechanisms and Logic of Dynamics) Laboratory, bridges digital circuits, synthetic biology, AI, and dynamic systems. The award spotlights Miskov-Zivanov’s pioneering approach to designing immunotherapies and teaching complex computational methods, setting the stage for profound future contributions in science and engineering.

Dr. Miskov-Zivanov’s project embodies the forefront of biomedical innovation, where AI-powered automation intersects with molecular engineering to tackle the enduring challenge of cancer therapy. By weaving together computational linguistics, graph theory, machine learning, and synthetic biology, she charts a new course toward more efficient, interpretable, and impactful immunotherapy design. The convergence of these fields promises to accelerate discovery and ultimately transform patient outcomes in oncology.

Subject of Research: Artificial Intelligence-driven design of immunotherapy cells, focusing on CAR T cells and tumor-infiltrating lymphocytes.

Article Title: Artificial Intelligence-Driven Framework Poised to Revolutionize Immunotherapy Design

News Publication Date: Not specified in the provided content.

Web References:

• Natasa Miskov-Zivanov Faculty Page
• NSF Award Detail
• Pitt News on NSF EAGER Award
• MeLoDy Laboratory

Keywords: Cancer immunotherapy, Generative AI, Computer science, Artificial intelligence, Deep learning, Systems neuroscience, T lymphocytes, Immune system